Zoetis Inc. (ZTS) |
| 75.38 0.57 (0.76%) 10-12 13:48 |
| Open: | 74.98 |
| High: | 75.449 |
| Low: | 74.17 |
| Volume: | 1,419,338 |
| Market Cap: | 31,601(M) |
| PE Ratio: | 11.46 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 88.00 |
| Resistance 1: | 75.34 |
| Pivot price: | 71.56 |
| Support 1: | 71.28 |
| Support 2: | 68.77 |
| 52w High: | 148.3 |
| 52w Low: | 68.77 |
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
| EPS | 6.220 |
| Book Value | 0.000 |
| PEG Ratio | 6.80 |
| Gross Profit | 16.529 |
| Profit Margin (%) | 27.68 |
| Operating Margin (%) | 40.72 |
| Return on Assets (ttm) | 15.4 |
| Return on Equity (ttm) | 64.9 |
Sun, 11 Oct 2026
Zoetis Inc. (ZTS) options chain – Yahoo Finance - Yahoo Finance Singapore
Fri, 09 Oct 2026
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Thu, 08 Oct 2026
SAWGRASS ASSET MANAGEMENT LLC's Zoetis Inc(ZTS) Holding History - GuruFocus
Thu, 08 Oct 2026
Zoetis (ZTS) Maintains Quarterly Dividend at $0.53, Offering 2.9% Yield - GuruFocus
Thu, 08 Oct 2026
A December 1 payout is set as Zoetis (ZTS) declares its fourth-quarter dividend. - Stock Titan
Thu, 08 Oct 2026
Zoetis Declares Fourth Quarter 2026 Dividend - Business Wire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |